Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-02-05 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于获得创新药HSK39004吸入粉雾剂《药物临床试验批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (890 characters) from a pharmaceutical company about receiving an official clinical trial approval notice from the National Medical Products Administration for a new drug. It contains no financial data, no detailed report, and no mention of financial results or management changes. It is an official regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as it does not match any other specific category such as Annual Report, Earnings Release, or Legal Proceedings. The document is not a report itself but an announcement of regulatory approval.
2025-02-05 Chinese
第五届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company 海思科医药集团股份有限公司. It details the approval of establishing a subsidiary in the US, including voting results and procedural compliance. The document is short (673 characters) and focuses on board decisions rather than financial data or report content. It is not an annual or interim report, earnings release, or audit report. It is not a call transcript or investor presentation. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. Therefore, the correct classification is MANG with high confidence.
2025-02-05 Chinese
关于控股股东部分股份解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the release of pledged shares by a controlling shareholder. It details the number of shares released from pledge, the shareholder involved, and the cumulative pledge status. There is no financial performance data, no mention of financial results, no management discussion, and no regulatory certification. The content is focused on share pledge status, which is a capital structure related update but specifically about share pledge release rather than new share issuance or buyback. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share pledges or releases.
2025-02-05 Chinese
关于控股股东一致行动人减持计划实施完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the completion of a share reduction plan by controlling shareholders and their concerted actors. It details the number of shares reduced, the reduction period, prices, and the shareholders' holdings before and after the reduction. It references compliance with securities laws and regulatory guidelines on shareholder share reduction. There is no financial data, earnings, or management discussion. The document is a formal disclosure of a transaction in own shares by insiders (shareholders related to controlling shareholders). This fits the category of Transaction in Own Shares (POS). The document length is 2562 characters, which is short but contains detailed transaction data, not just a notice of a report publication or certification. Therefore, the classification is POS with high confidence.
2025-01-26 Chinese
关于签署募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for raised funds by the company. It details the fundraising amount, the use of funds, the opening of a special account for the funds, and the supervisory responsibilities of involved parties. The document does not contain financial statements or detailed financial performance data but rather focuses on the management and regulatory compliance of the fundraising proceeds. The length is under 5,000 characters and it is an announcement about the fundraising supervision agreement, not a full financial report or audit. Therefore, it fits best under Capital/Financing Update (CAP).
2025-01-23 Chinese
第五届董事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from the company 海思科医药集团股份有限公司. It details the decisions made during the fifth board's 22nd meeting, including approval of using idle raised funds for cash management. The document includes voting results and mentions compliance with laws and company bylaws. It does not contain financial statements or detailed financial data but is a formal announcement of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2025-01-22 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.